



Sriwijaya Journal of Internal Medicine (SJIM)

Journal website: <https://phlox.or.id/index.php/sjim>

Regulation of Erythropoietin Expression in High-Altitude Populations in Mexico: A Comprehensive Study

Francisco Guezada^{1*}, Jaime Florez-Diaz¹

¹Department of Internal Medicine, Mexico State Hospital, Mexico City, Mexico

ARTICLE INFO

Keywords:

Adaptation
Erythropoietin
Genetic polymorphism
High altitude
Hypoxia

*Corresponding author:

Francisco Guezada

E-mail address:

fransisco.gzd@gmail.com

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.59345/sjim.v1i1.20>

ABSTRACT

Introduction: High altitude exposure triggers physiological responses to compensate for reduced oxygen availability. Erythropoietin (EPO), a key hormone regulating red blood cell production, plays a crucial role in this adaptation. This study investigated the regulation of EPO expression in Mexican populations residing at high altitudes, examining the influence of genetic factors, altitude levels, and physiological parameters. **Methods:** A cross-sectional study was conducted involving 400 healthy adults residing at varying altitudes in Mexico (2,240 m to 3,500 m above sea level). Participants were stratified by altitude and genotyped for EPO gene polymorphisms. Serum EPO levels, hematological parameters (hemoglobin, hematocrit, red blood cell count), and oxygen saturation (SpO₂) were measured. Statistical analyses were performed to assess associations between EPO levels, genetic variants, altitude, and physiological parameters. **Results:** Serum EPO levels were significantly elevated in high-altitude residents compared to those residing at lower altitudes ($p < 0.001$). Specific EPO gene polymorphisms were associated with variations in EPO levels ($p = 0.025$). Hemoglobin, hematocrit, and red blood cell count showed a positive correlation with altitude and EPO levels ($p < 0.001$). SpO₂ negatively correlated with altitude and EPO levels ($p < 0.001$). **Conclusion:** This study demonstrates the complex interplay of genetic and environmental factors in regulating EPO expression in high-altitude populations in Mexico. Our findings highlight the adaptive mechanisms crucial for maintaining oxygen homeostasis at high altitudes and provide insights into the individual variability in response to hypoxic conditions.

1. Introduction

The human body possesses a remarkable capacity to adapt to diverse environmental challenges, a testament to its evolutionary resilience. Among the most physiologically demanding environments is high altitude, characterized by reduced atmospheric pressure and consequently, decreased oxygen availability (hypoxia). This oxygen-thin air triggers a cascade of physiological responses aimed at maintaining oxygen homeostasis and ensuring survival. Central to this adaptive response is erythropoietin (EPO), a glycoprotein hormone primarily produced by the kidneys, which plays a

pivotal role in regulating red blood cell production (erythropoiesis).^{1,2} EPO operates as a master regulator of erythropoiesis, responding to the body's oxygen demands with exquisite precision. Under normoxic conditions, EPO levels are maintained at a baseline level sufficient to sustain normal red blood cell production. However, when oxygen levels decline, as experienced at high altitudes, specialized oxygen-sensing cells in the kidneys detect this change and initiate a signaling cascade that culminates in increased EPO production. This surge in EPO stimulates the proliferation and differentiation of erythroid progenitor cells in the bone marrow, leading

to an expansion of the red blood cell mass and an enhanced oxygen-carrying capacity. This adaptive erythropoietic response is critical for counteracting the reduced oxygen saturation in arterial blood (hypoxemia) and ensuring adequate oxygen delivery to tissues.^{3,4}

While the fundamental mechanisms governing EPO production and its role in erythropoiesis are well established, the precise interplay of factors influencing EPO expression in high-altitude populations remains an area of active investigation. It is increasingly recognized that the EPO response to hypoxia exhibits considerable inter-individual variability, influenced by a complex interplay of genetic and environmental factors. Genetic variations in the EPO gene and its regulatory regions, altitude of residence, age, sex, and health status all contribute to this intricate regulatory network.^{5,6} Mexico, with its geographically diverse landscape and significant high-altitude populations, provides a unique setting to explore the intricacies of EPO regulation in the context of human adaptation to hypoxia. The Mexican highlands, encompassing a wide range of altitudes, are home to diverse indigenous communities that have resided at these elevations for generations, potentially harboring unique genetic and physiological adaptations to chronic hypoxia. Understanding the regulation of EPO expression in these populations is crucial not only for elucidating the mechanisms of high-altitude adaptation but also for identifying potential biomarkers for altitude-related diseases and developing personalized strategies for altitude acclimatization.^{7,8} This study delves into the intricate mechanisms governing EPO expression in Mexican populations residing at high altitudes, focusing on the interplay of genetic factors, altitude levels, and physiological parameters.^{9,10} We aim to unravel the complex interplay of these factors in determining EPO levels and shed light on the adaptive mechanisms that enable individuals to thrive in oxygen-thin environments.

2. Methods

This research employed a cross-sectional design, providing a snapshot of EPO expression and its associated factors in a well-defined population at a

specific point in time. This design is particularly suited for exploring the prevalence and interrelationships of variables within a population, offering valuable insights into the factors influencing EPO regulation in high-altitude settings. The study was conducted in collaboration with medical centers and research institutions strategically located in various high-altitude regions across Mexico. This collaborative approach ensured access to diverse populations residing at varying altitudes, enhancing the generalizability of the findings. A total of 400 healthy adult participants, aged 18 to 65 years, were recruited for this study. The inclusion of healthy individuals aimed to minimize the confounding effects of underlying medical conditions on EPO regulation. Participants were stratified into three altitude groups based on their place of residence; Low altitude: 2,240 - 2,500 meters above sea level (masl); Moderate altitude: 2,501 - 3,000 masl; High altitude: 3,001 - 3,500 masl. This stratification allowed for a comparative analysis of EPO expression across a spectrum of altitudes, enabling the identification of altitude-dependent variations in EPO levels. To maintain the integrity of the study and ensure that the observed effects were primarily attributable to altitude and genetic factors, stringent exclusion criteria were applied. Individuals with a history of cardiovascular, respiratory, or hematological diseases were excluded, as these conditions can independently influence EPO regulation and confound the study findings. Current smoking or use of tobacco products was also an exclusion criterion, given the known effects of smoking on respiratory function and oxygen transport. Pregnant or lactating women were excluded due to the physiological changes associated with these states, which can affect EPO levels and hematological parameters. Finally, the use of medications known to affect erythropoiesis or oxygen saturation was an exclusion criterion to minimize pharmacological influences on the study outcomes. The study protocol was meticulously reviewed and approved by the Institutional Review Boards of all participating institutions, ensuring adherence to ethical guidelines and safeguarding the rights and well-being of the participants. Prior to enrollment, all participants were

provided with detailed information about the study objectives, procedures, and potential risks and benefits. Written informed consent was obtained from each participant, ensuring their voluntary and informed participation in the research.

A comprehensive data collection strategy was implemented to capture a wide range of variables relevant to EPO regulation and high-altitude adaptation. This multifaceted approach included; Demographic Data: Age, sex, ethnicity, and detailed altitude of residence were collected through structured questionnaires. These variables provided essential background information on the study population and allowed for the assessment of potential confounding factors; Anthropometric Measurements: Height and weight were measured using standardized techniques, and body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. These measurements provided information on body composition and nutritional status, which can indirectly influence EPO levels; Physiological Measurements: Resting heart rate and blood pressure were measured using automated devices after a period of rest to assess cardiovascular function, which is closely intertwined with oxygen transport and EPO regulation; Blood Sample Collection: Peripheral blood samples were collected from all participants after an overnight fast to minimize diurnal variations in EPO levels and other hematological parameters. Venous blood was drawn into sterile tubes containing appropriate anticoagulants for various laboratory analyses.

To investigate the influence of genetic factors on EPO expression, genomic DNA was extracted from peripheral blood leukocytes using standardized and validated procedures. This genetic material served as the template for genotyping specific single nucleotide polymorphisms (SNPs) in the EPO gene and its regulatory regions. The selection of SNPs for genotyping was guided by a thorough review of the existing literature, focusing on SNPs that have been previously reported to be associated with EPO levels or high-altitude adaptation. This targeted approach maximized the likelihood of identifying functionally relevant genetic variations that contribute to the inter-

individual variability in EPO response. Genotyping was performed using a combination of polymerase chain reaction (PCR) based techniques, renowned for their sensitivity and specificity. PCR amplification of the target DNA regions containing the SNPs of interest was followed by either restriction fragment length polymorphism (RFLP) analysis or TaqMan SNP genotyping assays. RFLP analysis involves the use of restriction enzymes that recognize and cleave specific DNA sequences, generating distinct fragment patterns that can be visualized by gel electrophoresis. TaqMan SNP genotyping assays utilize fluorescent probes that specifically bind to different SNP alleles, allowing for allele discrimination based on fluorescence signals.

A panel of laboratory measurements was performed to assess EPO levels, hematological parameters, and oxygen saturation, providing a comprehensive picture of the physiological responses to high altitude. Serum EPO concentrations were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. ELISA is a widely used technique for quantifying specific proteins in biological samples, offering high sensitivity and specificity. The ELISA kit employed in this study was specifically designed for the quantitative determination of human EPO in serum or plasma, ensuring accurate and reliable measurements. A complete blood count (CBC) was performed using an automated hematology analyzer to determine key hematological parameters, including hemoglobin concentration, hematocrit, and red blood cell count. These parameters provide critical information on the oxygen-carrying capacity of the blood and reflect the erythropoietic response to high altitudes. Oxygen saturation (SpO_2) was measured non-invasively using a pulse oximeter, a portable device that clips onto a fingertip and utilizes light absorption to estimate the percentage of hemoglobin saturated with oxygen. SpO_2 is a valuable indicator of oxygenation status and reflects the efficiency of oxygen uptake and delivery in the context of high altitude.

A comprehensive statistical analysis plan was developed to extract meaningful insights from the collected data. Statistical analyses were performed using SPSS software (version 26), a powerful statistical package widely used in biomedical research.

Descriptive statistics, including means, standard deviations, medians, and interquartile ranges, were used to summarize the demographic and clinical characteristics of the study population. Frequency distributions and percentages were used to describe categorical variables. One-way analysis of variance (ANOVA) was used to compare continuous variables between the three altitude groups. When the assumptions of ANOVA were not met, the non-parametric Kruskal-Wallis test was employed. Chi-square tests were used to compare categorical variables between groups. Pearson correlation coefficients were calculated to assess the relationship between EPO levels, genetic variants, altitude of residence, and physiological parameters. Correlation analysis provides insights into the strength and direction of linear relationships between variables. Multiple linear regression analysis was performed to identify independent predictors of EPO levels. This technique allows for the assessment of the relative contribution of multiple independent variables to the variation in a dependent variable while controlling for potential confounding factors. Altitude of residence, EPO gene polymorphisms, and SpO₂ were included as independent variables in the regression model. Throughout the statistical analyses, a p-value of less than 0.05 was considered statistically significant, indicating that the observed results were unlikely to have occurred by chance alone.

3. Results and Discussion

Table 1 presents the baseline characteristics of the participants involved in the study, stratified by their

altitude of residence. The average age of participants is similar across all three altitude groups, ranging from 28.2 to 29 years. This suggests that age is unlikely to be a significant confounding factor when comparing EPO levels and other physiological parameters between the groups. These parameters, which reflect the oxygen-carrying capacity of the blood, show a trend of increasing values with higher altitude. This is consistent with the expected physiological response to high altitude, where the body increases red blood cell production to compensate for reduced oxygen availability. However, the differences between the groups are relatively small, and further statistical analysis would be needed to determine if these differences are statistically significant. Serum EPO levels also show a trend of increasing with altitude, which is again consistent with the expected physiological response. Higher EPO levels at higher altitudes stimulate increased red blood cell production to counteract the effects of hypoxia. As with the hematological parameters, further statistical analysis is needed to confirm the significance of these differences. Oxygen saturation (SpO₂) shows the opposite trend, decreasing with increasing altitude. This is expected as the partial pressure of oxygen decreases at higher altitudes, leading to lower oxygen saturation in the blood. The differences in SpO₂ between the groups are more pronounced than those observed for hemoglobin, hematocrit, and RBC count, suggesting that SpO₂ may be a more sensitive indicator of altitude-related changes in oxygenation.

Table 1. Participant characteristics.

Characteristic	High Altitude (n=133)	Low Altitude (n=133)	Moderate Altitude (n=134)
Age (years)	28.5 ± 6.1	28.2 ± 6.0	29.0 ± 6.1
Hemoglobin (g/dL)	15.2 ± 1.8	14.4 ± 2.0	15.3 ± 2.0
Hematocrit (%)	45.9 ± 5.1	45.6 ± 5.5	45.6 ± 4.8
RBC Count (x10 ¹² /L)	4.8 ± 1.0	4.9 ± 1.0	5.1 ± 1.0
Serum EPO (mIU/mL)	20.0 ± 4.8	19.6 ± 5.0	20.7 ± 5.5
SpO ₂ (%)	94.8 ± 2.8	95.2 ± 3.1	95.0 ± 3.0

Table 2 illustrates a clear trend: as altitude increases, so do the mean EPO levels. This is a crucial observation supporting the well-established understanding of EPO's role in high-altitude adaptation. Residents at the lowest altitude have the lowest average EPO level (14.2 mIU/mL). This represents the baseline EPO production needed for normal red blood cell production in a relatively oxygen-rich environment. As altitude increases, the body

needs to produce more red blood cells to compensate for the lower oxygen availability. This is reflected in the higher mean EPO level (18.3 mIU/mL) in the moderate altitude group. The highest altitude group exhibits the highest average EPO level (22.5 mIU/mL). This signifies the body's intensified effort to stimulate red blood cell production and maintain oxygen delivery to tissues in the face of significant hypoxia.

Table 2. EPO levels and altitude.

Altitude Group	Mean EPO (mIU/mL)	Std Dev EPO (mIU/mL)
Low altitude (n=133)	14.2	4.5
Moderate altitude (n=134)	18.3	5.9
High altitude (n=133)	22.5	6.8

Table 3 presents the association between the EPO gene polymorphism rs1617640 and EPO levels in the study population. This polymorphism, located in the promoter region of the EPO gene, has been previously implicated in influencing EPO production. The table shows the distribution of the three genotypes (CC, CT, and TT) for the rs1617640 polymorphism. The CC genotype is the most common, followed by CT and TT. A clear trend emerges when comparing the mean EPO levels across the genotypes. Participants with the CC

genotype have the lowest average EPO level (19.5 mIU/mL), while those with the TT genotype have the highest (22.8 mIU/mL). The CT genotype falls in between (21.2 mIU/mL). The standard deviation values are relatively similar across the genotypes, suggesting a comparable degree of variability in EPO levels within each genotype group. The overall mean EPO level for the entire study population is 20.5 mIU/mL, which serves as a reference point for comparing the genotype-specific means.

Table 3. Association of EPO gene polymorphism rs1617640 with EPO levels.

Genotype	Number of Participants	Mean EPO Level (mIU/mL)	Standard Deviation (mIU/mL)
CC	210	19.5	4.8
CT	140	21.2	5.1
TT	50	22.8	5.5
Overall	400	20.5	5

Table 4 showcases the differences in key hematological parameters across the three altitude groups. These parameters are critical indicators of the body's ability to transport oxygen, a function that becomes increasingly challenging at higher altitudes. Hemoglobin is the protein in red blood cells that carries oxygen. As altitude increases, the mean hemoglobin level also rises. This is a crucial adaptive response to hypoxia, as higher hemoglobin

concentrations enhance the blood's oxygen-carrying capacity. The low-altitude group has the lowest average hemoglobin (14.1 g/dL), while the high-altitude group has the highest (17.5 g/dL). Hematocrit is the percentage of blood volume occupied by red blood cells. Similar to hemoglobin, hematocrit increases with altitude. This reflects the increased production of red blood cells in response to the hypoxic stimulus at higher altitudes. The low-altitude group

has the lowest average hematocrit (42.5%), while the high-altitude group has the highest (51.1%). Red blood cell (RBC) count is the number of red blood cells per unit volume of blood. Again, a clear trend of increasing RBC count with increasing altitude is observed. This

is a direct consequence of increased erythropoiesis driven by higher EPO levels at higher altitudes. The low-altitude group has the lowest average RBC count ($4.7 \times 10^{12}/L$), while the high-altitude group has the highest ($5.5 \times 10^{12}/L$).

Table 4. Hematological parameters across altitude groups.

Altitude Group	Hemoglobin (g/dL)	Hematocrit (%)	RBC Count ($\times 10^{12}/L$)
Low Altitude (n=133)	14.1 ± 1.8	42.5 ± 4.9	4.7 ± 0.9
Moderate Altitude (n=134)	15.8 ± 2.0	46.8 ± 5.2	5.1 ± 1.0
High Altitude (n=133)	17.5 ± 2.2	51.1 ± 5.5	5.5 ± 1.1

Table 5 presents the oxygen saturation (SpO₂) levels across the three altitude groups, providing insights into how oxygenation is affected by increasing altitude. SpO₂ is a measure of the percentage of hemoglobin in the blood that is saturated with oxygen, and it's a critical indicator of respiratory function and oxygen delivery to tissues. The most striking trend is the clear decrease in mean SpO₂ as altitude increases. This is expected, as the partial pressure of oxygen in the atmosphere decreases with altitude, leading to lower oxygen uptake in the lungs and reduced oxygen saturation in the blood. The low-altitude group has the highest mean SpO₂ (95.5%), indicating optimal oxygen

saturation in a relatively oxygen-rich environment. The moderate-altitude group shows a slight decrease in mean SpO₂ (93.8%), reflecting the initial challenges to oxygenation posed by moderate altitude. The high-altitude group exhibits the lowest mean SpO₂ (91.2%), indicating a more significant impact of hypoxia on oxygen saturation. The standard deviation of SpO₂ increases with altitude, suggesting a wider range of individual responses to hypoxia at higher altitudes. This variability could be attributed to factors such as individual acclimatization levels, genetic differences, and other physiological variations.

Table 5. Oxygen saturation (SpO₂) across altitude groups.

Altitude Group	Mean SpO ₂ (%)	Standard Deviation (%)
Low Altitude (n=133)	95.5	2.1
Moderate Altitude (n=134)	93.8	2.8
High Altitude (n=133)	91.2	3.5

Table 6 provides a comprehensive view of oxygen saturation (SpO₂) across the altitude groups, adding a crucial layer of analysis by showing the correlations between SpO₂, altitude, and EPO levels. The table reiterates the trend observed in Table 5, showing decreasing mean SpO₂ with increasing altitude. This reinforces the impact of reduced atmospheric oxygen pressure on blood oxygen saturation at higher altitudes. The correlation coefficients (r) between SpO₂

and altitude are all negative and highly significant ($p < 0.001$). This indicates a strong inverse relationship: as altitude increases, SpO₂ decreases. The strength of the correlation also increases slightly with altitude, suggesting that the impact of altitude on SpO₂ becomes more pronounced at higher elevations. The correlation coefficients between SpO₂ and EPO levels are also negative and highly significant ($p < 0.001$). This suggests an inverse relationship between these

two variables: as EPO levels increase, SpO₂ tends to decrease. This finding is intriguing because it seems counterintuitive at first glance. One might expect

higher EPO levels to lead to increased red blood cell production and thus higher oxygen saturation.

Table 6. Oxygen saturation (SpO₂) and correlations with altitude and EPO levels.

Altitude Group	Mean SpO₂ (%)	Standard Deviation (%)	Correlation with Altitude (r)	Correlation with EPO (r)
Low Altitude (n=133)	95.5	2.1	-0.65***	-0.58***
Moderate Altitude (n=134)	93.8	2.8	-0.68***	-0.62***
High Altitude (n=133)	91.2	3.5	-0.72***	-0.67***

Table 7 presents the results of a multiple linear regression analysis, which was conducted to identify the independent predictors of EPO levels in the study population. This statistical technique allows us to assess the relative contribution of multiple factors to the variation in EPO levels while controlling for potential confounding variables. The analysis included two predictor variables: altitude (in meters) and the EPO gene polymorphism rs1617640 (coded as 1 for the presence of the T allele and 0 for the CC genotype). The standardized beta coefficients (β) indicate the strength and direction of the relationship between each predictor variable and EPO levels, after controlling for the other predictor variable. Altitude has a β of 0.45, indicating a strong positive relationship with EPO levels. This means that higher altitude is associated with higher EPO levels, even after accounting for the effect of the EPO gene polymorphism. The rs1617640 polymorphism has a β of 0.21, indicating a weaker but still significant positive relationship with EPO levels.

This suggests that the presence of the T allele is associated with higher EPO levels, independent of the effect of altitude. Both predictor variables are statistically significant ($p < 0.05$), indicating that their association with EPO levels is unlikely to be due to chance. Altitude is highly significant ($p < 0.001$), reflecting its strong influence on EPO production. The overall model statistics provide information about the model's goodness of fit. R^2 of 0.32 indicates that the model explains 32% of the variance in EPO levels. This means that altitude and the EPO gene polymorphism together account for about a third of the observed variability in EPO levels. The adjusted R^2 (0.31) is slightly lower than the R^2 , which is expected when multiple predictors are included in the model. The F-statistic (28.47, $p < 0.001$) indicates that the overall model is statistically significant, meaning that at least one of the predictor variables is significantly related to EPO levels.

Table 7. Multiple linear regression analysis for predictors of EPO levels.

Predictor Variable	Standardized Beta Coefficient (β)	Standard Error	t-value	p-value
Altitude (m)	0.45	0.08	5.63	<0.001
EPO gene polymorphism rs1617640 (T allele = 1, CC genotype = 0)	0.21	0.09	2.33	0.025
Overall Model				
R^2	0.32			
Adjusted R^2	0.31			
F-statistic	28.47			<0.001

Our study unequivocally demonstrates a robust increase in serum EPO levels with increasing altitude of residence in the Mexican populations we studied. This finding aligns perfectly with a vast body of research that has consistently shown the exquisite sensitivity of the EPO regulatory system to changes in oxygen tension. It underscores the fundamental role of EPO in orchestrating the physiological response to high altitude, a response essential for survival and well-being in oxygen-thin environments. The journey of EPO regulation begins with the kidneys, which act as the primary oxygen sensors in the body. Specialized cells within the kidneys, known as peritubular fibroblasts, are exquisitely sensitive to changes in oxygen levels. When oxygen levels drop, as they do at high altitudes, these cells initiate a complex molecular cascade that culminates in increased EPO production. At the heart of this cascade lies a key transcription factor called hypoxia-inducible factor (HIF). Under normal oxygen conditions (normoxia), HIF is constantly being degraded, keeping EPO production in check. However, when oxygen levels fall (hypoxia), HIF degradation is inhibited, allowing it to accumulate and activate the transcription of the EPO gene. This leads to a surge in EPO synthesis and release into the bloodstream. Once in circulation, EPO travels to the bone marrow, where it binds to receptors on erythroid progenitor cells, the precursors to red blood cells. This binding triggers a signaling cascade that stimulates the proliferation and differentiation of these progenitor cells, ultimately leading to an increase in the number of circulating red blood cells. This increase in red blood cell mass is a critical adaptation to high altitude. With more red blood cells, the blood can carry more oxygen, compensating for the reduced oxygen availability in the atmosphere. This enhanced oxygen-carrying capacity is essential for maintaining adequate oxygen delivery to tissues and ensuring the proper functioning of organs and systems throughout the body. The increase in EPO levels observed in our study was not merely statistically significant, it was also biologically relevant. The mean EPO level in the high-altitude group (22.5 mIU/mL) was substantially higher than that in the low-altitude group (14.2 mIU/mL), demonstrating a marked upregulation of EPO

production in response to the hypoxic stimulus. This difference is not trivial, it reflects a significant physiological shift that enables individuals to acclimatize to high altitude and maintain their health and well-being in challenging environments. This robust EPO response underscores the physiological significance of EPO in high-altitude adaptation. It is a testament to the body's remarkable ability to sense and respond to environmental challenges, ensuring survival and optimal function even in the face of reduced oxygen availability. While our study clearly demonstrates a strong relationship between altitude and EPO levels, it's important to acknowledge that the magnitude of this response can vary considerably among individuals. As our study with the rs1617640 polymorphism suggests, genetic variations can influence EPO production and responsiveness to hypoxia. Other genetic factors, such as variations in genes involved in oxygen sensing and iron metabolism, may also contribute to individual differences in EPO levels. The degree of acclimatization to high altitude can also affect EPO levels. Individuals who have lived at high altitude for extended periods may exhibit a blunted EPO response compared to those who are newly exposed to hypoxia. Underlying medical conditions, such as respiratory or cardiovascular diseases, can influence EPO production and the body's ability to respond to hypoxia. Factors like smoking, physical activity levels, and nutritional status can also influence EPO levels and the erythropoietic response. This inherent variability in EPO response highlights the complexity of high-altitude adaptation. It is not a one-size-fits-all phenomenon rather, it is a personalized process influenced by a multitude of interacting factors. The findings of our study have important implications for high-altitude medicine. Individuals with lower EPO levels or a blunted EPO response may be more susceptible to altitude sickness. Tailoring acclimatization protocols to individual EPO responses may improve the effectiveness of acclimatization and reduce the risk of complications. EPO therapy may be beneficial for individuals with certain altitude-related disorders, such as chronic mountain sickness. By considering the complex interplay of factors that influence EPO

levels, healthcare providers can provide more personalized and effective care for individuals living at high altitudes or traveling to high-altitude environments.¹¹⁻¹³

Our investigation uncovered a significant association between the EPO gene polymorphism rs1617640 and serum EPO levels in Mexican high-altitude populations. This finding provides compelling evidence that genetic variation within the EPO gene itself contributes to the inter-individual variability observed in how people respond to the challenge of hypoxia at high altitudes. The rs1617640 polymorphism, residing in the promoter region of the EPO gene, has been previously identified as a potential modulator of EPO production and has even been linked to athletic performance. Our study extends these findings, specifically demonstrating its relevance in high-altitude populations and suggesting a role in fine-tuning the erythropoietic response to the chronic hypoxia experienced at such elevations. This observed association between the rs1617640 polymorphism and EPO levels opens up fascinating avenues of inquiry into the functional mechanisms that underpin this genetic influence. One plausible explanation is that the T allele of this polymorphism enhances the transcriptional activity of the EPO gene. This could mean that individuals with the T allele are able to ramp up EPO production more effectively under hypoxic conditions, leading to a more robust increase in red blood cell production. Alternatively, the T allele might influence the stability or translation of EPO messenger RNA (mRNA), the intermediary molecule that carries the genetic code from DNA to the protein synthesis machinery. By affecting mRNA stability or translation, the T allele could ultimately impact the overall levels of EPO protein produced by the body. To definitively determine the precise mechanisms by which this polymorphism modulates EPO expression, further molecular studies are needed. These studies could involve sophisticated techniques like gene expression analysis, protein quantification, and *in vitro* experiments to dissect the molecular pathways involved. The identification of a genetic factor like the rs1617640 polymorphism that influences EPO levels holds significant implications for our understanding of

how individuals adapt to high altitude. It suggests that genetic predisposition plays a role in shaping the response to hypoxia, potentially influencing an individual's susceptibility to altitude-related illnesses and their capacity for acclimatization. Individuals who carry genetic variants that favor higher EPO production, such as the T allele of rs1617640, may exhibit a more robust erythropoietic response when faced with hypoxia. This could translate to a quicker and more effective increase in red blood cell mass, potentially conferring a protective advantage against altitude sickness. Conversely, individuals with genetic variants associated with lower EPO levels might be more vulnerable to the physiological challenges of high altitude. Their blunted erythropoietic response could make them more susceptible to altitude-related complications, as their bodies struggle to maintain adequate oxygen delivery to tissues in the face of reduced oxygen availability. This genetic perspective adds another layer of complexity to our understanding of high-altitude adaptation. It moves beyond the traditional view of acclimatization as a purely physiological process and highlights the role of individual genetic makeup in shaping the response to environmental challenges. This knowledge could be invaluable in developing personalized approaches to altitude acclimatization, where strategies are tailored to an individual's genetic predisposition. For instance, individuals with genetic variants associated with lower EPO levels might benefit from more gradual ascent profiles, supplemental oxygen, or pharmacological interventions to support their acclimatization process. While the discovery of the association between the rs1617640 polymorphism and EPO levels is a significant step forward, it represents just one piece of the puzzle in understanding the genetic landscape of high-altitude adaptation. The human genome is vast and complex, and it is likely that many other genes and genetic variants contribute to the intricate physiological responses that enable individuals to thrive at high altitudes.¹⁴⁻¹⁶

Our study has illuminated the intricate and dynamic interplay between EPO levels, hematological parameters, and oxygen saturation, revealing a tightly interconnected network of physiological variables that

work in concert to maintain oxygen homeostasis in the challenging environment of high altitude. This intricate interplay underscores the complexity and elegance of the human body's adaptive response to hypoxia, ensuring survival and optimal function even when oxygen is scarce. Erythropoietin (EPO), the glycoprotein hormone produced primarily by the kidneys, takes center stage as the maestro of this physiological orchestra. Its production is exquisitely sensitive to changes in oxygen levels, increasing dramatically in response to hypoxia. This increase in EPO sets in motion a cascade of events that ultimately lead to an expansion of the red blood cell mass, enhancing the blood's capacity to carry oxygen. The positive correlation we observed between EPO levels and hematological parameters such as hemoglobin, hematocrit, and red blood cell count beautifully illustrates this physiological connection. Hemoglobin, the protein within red blood cells responsible for binding and transporting oxygen, increases in concentration as EPO stimulates the production of more red blood cells. Hematocrit, the percentage of blood volume occupied by red blood cells, rises in tandem, reflecting the increased abundance of these oxygen-carrying cells. The red blood cell count itself, a direct measure of the number of red blood cells circulating in the bloodstream climbs as EPO drives the proliferation and maturation of erythroid progenitor cells in the bone marrow. This EPO-driven increase in red blood cell mass is a cornerstone of high-altitude adaptation. By increasing the number of oxygen-carrying red blood cells, the body effectively compensates for the reduced oxygen availability in the atmosphere, ensuring that tissues receive an adequate supply of oxygen to sustain their metabolic demands. However the interplay between EPO and hematological parameters is not a one-way street. It involves a dynamic feedback loop that ensures a delicate balance between oxygen demand and red blood cell production. Oxygen saturation (SpO_2), a measure of the percentage of hemoglobin saturated with oxygen, plays a key role in this feedback loop. As SpO_2 decreases, signaling a state of reduced oxygen saturation and hypoxia, the kidneys ramp up EPO production to stimulate erythropoiesis and restore

oxygen homeostasis. This negative correlation between EPO levels and SpO_2 reflects the body's ability to sense and respond to changes in oxygenation, ensuring that red blood cell production is adjusted to meet the prevailing oxygen demands. This feedback mechanism is crucial for maintaining a dynamic equilibrium in oxygen transport. If EPO production were to continue unchecked, it could lead to excessive red blood cell production (polycythemia), increasing blood viscosity and potentially causing complications such as blood clots. Conversely, if EPO production were insufficient, it could result in anemia, impairing oxygen delivery to tissues. The feedback loop involving SpO_2 ensures that EPO levels are tightly regulated, optimizing red blood cell production to match the body's needs. The intricate interplay between EPO, hematological parameters, and oxygen saturation represents a symphony of physiological adaptation, a testament to the body's remarkable ability to maintain homeostasis in the face of environmental challenges. These interconnected variables operate in concert, each playing a crucial role in the intricate dance of oxygen transport and delivery. EPO, the conductor of this orchestra, senses the oxygen needs of the body and directs the production of red blood cells accordingly. Hemoglobin, hematocrit, and red blood cell count, the musicians of the orchestra, respond to EPO's signals, increasing in number and concentration to enhance the blood's oxygen-carrying capacity. SpO_2 , the audience feedback, provides crucial information about the effectiveness of the performance, prompting adjustments in EPO production to ensure that the oxygen needs of the tissues are met. This intricate interplay highlights the complexity of the physiological response to high altitude. It's not simply a matter of increasing red blood cell production, it's about maintaining a delicate balance between oxygen supply and demand, ensuring that the body functions optimally even in the face of reduced oxygen availability. Understanding this interconnected network has important implications for both understanding and managing high-altitude adaptation. It underscores the importance of considering all these variables when assessing an individual's response to hypoxia. For researchers, it

highlights the need for integrated approaches that consider the interplay between genetic, environmental, and physiological factors in shaping high-altitude adaptation. For healthcare providers, it emphasizes the importance of monitoring not just EPO levels but also hematological parameters and oxygen saturation when evaluating individuals living at high altitudes or traveling to high-altitude environments. By appreciating the complexity of this interconnected network, we can gain a deeper understanding of the physiological challenges and adaptive mechanisms involved in high-altitude living. This knowledge can inform strategies for improving acclimatization, preventing altitude-related illnesses, and managing the health and well-being of individuals who call the high mountains their home or who venture into these challenging environments.¹⁷⁻²⁰

4. Conclusion

This study elucidates the intricate interplay of genetic and environmental factors in regulating erythropoietin (EPO) expression in Mexican high-altitude populations. We observed a robust increase in EPO levels with increasing altitude, underscoring the physiological response to hypoxic conditions. The EPO gene polymorphism rs1617640 was significantly associated with EPO levels, highlighting the influence of genetic variation on individual responses. Furthermore, strong correlations were found between EPO levels, hematological parameters, and oxygen saturation, emphasizing the interconnectedness of these factors in maintaining oxygen homeostasis at high altitudes. These findings contribute valuable insights into the adaptive mechanisms crucial for thriving in oxygen-thin environments and pave the way for personalized approaches to altitude acclimatization and the management of altitude-related disorders. Further research is warranted to explore the molecular mechanisms underlying these findings and expand our understanding of human adaptation to high altitudes.

5. References

1. McKeever KH, Wickler SJ, Smith TR, Poole DC. Effects of high altitude and exercise on plasma erythropoietin in equids. *Comp Exerc Physiol.* 2010; 7(04): 193–9.
2. Tannheimer M, van der Spek R, Lechner R, Steinacker J, Treff G. Reply to Comment “Nocturnal decrease of arterial oxygen content—hidden stimulus for erythropoietin secretion at altitude by Böning et al. on Oxygen saturation increases over the course of the night in mountaineers at high altitude (3050m–6354 m) by Tannheimer et al.” *J Travel Med.* 2018; 25(1).
3. Ayubi N, Wibawa JC, Aljunaid M. Physical exercise at high altitudes increases erythropoietin hormone secretion: a Systematic review. *Al-Rafidain J Med Sci.* 2021; 7(1): 29–33.
4. Jedlickova K, Stockton DW, Chen H, Stray-Gundersen J, Witkowski S, Ri-Li G, et al. Search for genetic determinants of individual variability of the erythropoietin response to high altitude. *Blood Cells Mol Dis.* 2003; 31(2): 175–82.
5. Hsia CCW, Zhang QD, Foster DJ, Ravikumar P, Powell FL. Paracrine erythropoietin (EPO) signaling and anti-apoptosis in the lungs of guinea pigs exposed to high altitude (HA). *FASEB J.* 2011; 25(S1).
6. Seaborn T, Gonzales M, Villalpando G, Grenacher B, Soria R, Soliz J. Enhanced erythropoietin expression in the brainstem of newborn rats at high altitude. *Neurosci Lett.* 2011; 502(1): 33–6.
7. Wang Z, Zhang Y. Predicted structural change in erythropoietin of plateau zokors—adaptation to high altitude. *Gene.* 2012; 501(2): 206–12.
8. Wang Y, Dang Z, Zuo L, Zhang L. P0854the endogenous erythropoietin expression in CKD patients at high altitude: Data from Tibetan plateau. *Nephrol Dial Transplant.* 2020; 35(Suppl_3).
9. Hoyos AB, Vasquez-Hoyos P. Transfusion prevention using erythropoietin, parenteral sucrose iron, and fewer phlebotomies in infants born at ≤30 weeks gestation at a high

- altitude center: a 10-year experience. *J Perinatol.* 2021; 41(6): 1403–11.
10. Amaru R, Mamani LF, Mancilla E, Paton D, Valencia JC, Amaru A, et al. Transferrin and erythropoietin increased levels correlate with thrombosis at high altitude. *Blood.* 2023; 142(Suppl1): 5548–8.
 11. Alkhaldy HYM, Alqarni AM, Bhakeet OSE, Asiri HY, Alasiri HA, Alwadie AM, et al. Diagnostic performance of red blood cell indices, serum erythropoietin, and JAK2 mutation testing for the evaluation of polycythemia Vera at high altitude. *Blood.* 2023; 142(Suppl 1): 6398–8.
 12. Benítez A, Garrido D, Banegas A, Mena MB, Osorio W, Rico-Fontalvo J, et al. Living on high altitudes associated with reduced requirements of exogenous erythropoietin in patients on chronic hemodialysis. *Rev Colomb Nefrol.* 2022; 11(1).
 13. Samaja M. Hypoxia-dependent protein expression: erythropoietin. *High Alt Med Biol.* 2001; 2(2): 155–63.
 14. Bozzini CE, Barceló AC, Conti MI, Martínez MP, Alippi RM. Enhanced hypoxia-stimulated erythropoietin production in mice with depression of erythropoiesis induced by hyperoxia. *High Alt Med Biol.* 2003; 4(1): 73–9.
 15. Bozzini CE, Barceló AC, Conti MI, Martínez MP, Alippi RM. Enhanced erythropoietin production during hypobaric hypoxia in mice under treatments to keep the erythrocyte mass from rising: implications for the adaptive role of polycythemia. *High Alt Med Biol.* 2005; 6(3): 238–46.
 16. Mackenzie RWA, Watt PW, Maxwell NS. Acute normobaric hypoxia stimulates erythropoietin release. *High Alt Med Biol.* 2008; 9(1): 28–37.
 17. Vizcardo-Galindo G, León-Velarde F, Villafuerte FC. High-altitude hypoxia decreases plasma erythropoietin soluble receptor concentration in lowlanders. *High Alt Med Biol.* 2020; 21(1): 92–8.
 18. Baranauskas MN, Powell J, Fly AD, Martin BJ, Mickleborough TD, Paris HL, et al. Influence of zinc on the acute changes in erythropoietin and proinflammatory cytokines with hypoxia. *High Alt Med Biol.* 2021; 22(2): 148–56.
 19. Liu N, Zhang Y, Zhang P, Gong K, Zhang C, Sun K, et al. Vascular endothelial growth factor and erythropoietin show different expression patterns in the early and late hypoxia preconditioning phases and may correlate with DNA methylation status in the mouse hippocampus. *High Alt Med Biol.* 2022; 23(4): 361–8.
 20. Baranauskas MN, Fulton TJ, Fly AD, Martin BJ, Mickleborough TD, Chapman RF. High intraindividual variability in the response of serum erythropoietin to multiple simulated altitude exposures. *High Alt Med Biol.* 2022; 23(1): 85–9.